Posts for Ticker ‘OCLS’

BioHealth Business Daily (BMRN, DVAX, SEPR, STEM, PCYC, OCLS)

biotech imageToday is an unusually active day for many emerging biotech stocks in the news and we are seeing significant moves in response. We have more detail on each with appropriate links through to more analysis and data at BioHealthInvestor.com or VSInvestor.com:

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is seeing exponential trading volume in stock and options after a 10% rise today.

Dynavax Technologies Corporation (NASDAQ: DVAX) is up over 50%after the FDA removed a clinical hold on its hepatitis treatment.

The fight over the Sepracor, Inc. (NASDAQ: SEPR) acquisition has now gone to the level of a class action status.  We noted the very low P/E and multiple valuations yesterday on this one.

StemCells, Inc. (NASDAQ: STEM) traded slightly higher on word that it will soon begin a study with the University of California, San Francisco Children’s Hospital using purified human neural stem cells as a possible treatment for Pelizaeus-Merzbacher Disease.

Pharmacyclics Inc. (NASDAQ: PCYC) was trading up on news that its right offering is oversubscribed.

Oculus Innovative Sciences, Inc. (NASDAQ: OCLS) is trading higher on report that it has been assigned a Medicare HCPCS code for its recently introduced Microcyn Skin & Wound HydroGel.

JON C. OGG
SEPTEMBER 10, 2009

Posted on: September 10, 2009 – 1:38 pm in Biotech, Drug companies, HI/LOW, Trading Alert, , , , , ,

Oculus Files To Sell More Securities Than Its Market Cap (OCLS)

Oculus Innovative Sciences, Inc. (NASDAQ: OCLS) has just filed a shelf registration that would allow the company to sell up to $75 million in securities.  The offering can be in stock, debt, warrants, or preferred shares.  The use of proceeds is for general corporate purposes.

There is just one small problem: The company’s market cap is $73.6 million shares.

Oculus has developed, manufactures, and sells a family of products intended to prevent and treat infections in chronic and acute wounds.  Its platform Microcyn is a proprietary oxychlorine small molecule formulation that is designed to treat a wide range of organisms that cause disease, including viruses, fungi, spores and antibiotic resistant strains of bacteria, in wounds.  Microcyn is NOT approved by the FDA.  Its device product is cleared for sale in the United States as a medical device for wound cleaning, or debridement, lubricating, moistening and dressing; is a device under CE Mark in Europe with anti-infective claims; and is approved as a drug in India and as an antiseptic in Mexico.

It recently began enrolling patients in Phase II Microcyn studies in mildly infected diabetic foot ulcers and is currently pursuing strategic partnerships to assess potential applications for Microcyn in several other markets.

Shares rose some 6% today to $5.55, and shares are only down 0.8% in after-hours trading. 

Jon C. Ogg
February 13, 2008

Posted on: February 13, 2008 – 5:12 pm in Medical, Secondary Offering, , ,